3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
127
Neoplasm Metastasis
14
Neoplasms
9
Advanced Breast Cancer
6
Endometrial Neoplasms
5
Recurrence
4
Hereditary Sensory and Autonomic Neuropathies
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Lobular
3
Carcinoma, Ductal, Breast
3
Squamous Cell Carcinoma of Head and Neck
2
Polycystic Ovary Syndrome
2
Osteoporosis
2
Neoplasms by Site
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Breast Neoplasms, Male
2
Breast Diseases
2
Bone Diseases, Metabolic
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Osteitis Deformans
1
Multiple Endocrine Neoplasia Type 1
1
Mesothelioma, Malignant
1
Interventions
Pemetrexed
9
Carboplatin
7
pembrolizumab
6
Cisplatin
6
130-nm albumin-bound paclitaxel
6
Paclitaxel
5
Nivolumab
5
Gemcitabine
5
palbociclib
4
napabucasin
4
durvalumab
4
Fulvestrant
4
Bevacizumab
4
ribociclib
3
osimertinib
3
abemaciclib
3
Mitomycin
3
Irinotecan
3
Fluorouracil
3
Drug Therapy
3
Anastrozole
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pralsetinib
2
patritumab
2
ficlatuzumab
2
exemestane
2
atezolizumab
2
Watchful Waiting
2
Trabectedin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Site
×
Letrozole
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled